Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9

Affiliations

¹ University of Munich, Munich, Germany; Department of Urology, University of Freiburg, Germany. Electronic address: christian.gratzke@med.uni-muenchen.de.
² Astellas Pharma Inc., Chertsey, UK.

Comment

Christian Gratzke et al. Eur Urol. 2019 Mar.

. 2019 Mar;75(3):e59-e60.

doi: 10.1016/j.eururo.2018.10.001. Epub 2018 Oct 26.

¹ University of Munich, Munich, Germany; Department of Urology, University of Freiburg, Germany. Electronic address: christian.gratzke@med.uni-muenchen.de.
² Astellas Pharma Inc., Chertsey, UK.

No abstract available

Comment on

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Gratzke C, et al. Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1. Eur Urol. 2018. PMID: 29866467 Clinical Trial.
Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9.
Lee SR, Park BW, Kim JH. Lee SR, et al. Eur Urol. 2019 Mar;75(3):e57-e58. doi: 10.1016/j.eururo.2018.10.002. Epub 2018 Oct 14. Eur Urol. 2019. PMID: 30327271 No abstract available.